Merck reports that its Phase 3 TroFuse-005 trial evaluating the investigational antibody-drug conjugate sacituzumab tirumotecan met its primary endpoints in certain patients with advanced or recurrent endometrial cancer.
A legal analysis reviews how an FDA guidance issued last year is reshaping how pharmaceutical and medical device companies can communicate scientific information about off-label uses of approved products, while it also creates new compliance challenges for industry.
